Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance. The present paper presents, for the first time in Russia, a comparative pharmacoeconomic analysis of using mirabegron (Betmiga®) to treat overactive bladder (OAB). Materials and methods. Three medical technologies were evaluated: treatment of OAB with mirabegron 50 mg/day, solifenacin 5 mg/day and solifenacin 10 mg/day. In addition, the strategies of mirabegron and botulinum toxin type A were analyzed as a result of simulating the second-line treatment. Results. When modeling for 1-year horizon, the lowest cost was found in mirabegron strategy, which was 16% lower than with solifenacin. When comparing the second line strategies using mirabegron and botulinum toxin type A, costs of mirabegron group were 61% lower. According to the selected performance criteria, mirabegron was more effective in comparison with other strategies. The findings of the budget impact analysis revealed that using mirabegron was preferable compared with solifenacin as the first line treatment, and compared with botulinum toxin type A as the second-line treatment. The analysis of cost-effectiveness and availability of technology showed growth when using mirabegron strategy; there was an increase in the efficiency of mirabegron strategy relative to solifenacin strategy, accompanied by cost reduction and, as a consequence, reducing the burden on the budget. Conclusions. Thus, using mirabegron to treat OAB both as the first and the second line treatment is absolutely cost-effective and profitable medical technology.

Full Text

Restricted Access

About the authors

A. S Kolbin

First Pavlov State Medical University of St. Peterburg; Saint Petersburg State University

Email: аlex.kolbin@mail.ru
Dr.Med.Sci., Prof., Head of the Department of Clinical Pharmacology and Evidence-Based Medicine

I. A Vilyum

First Pavlov State Medical University of St. Peterburg; St. Petersburg a multi-disciplinary center of Minzdrav of Russia

Email: i-velum@yandex.ru

M. A Proskurin

Saint Petersburg State University

Email: proskurin.m@gmail.com

Yu. E Balykina

Saint Petersburg State University

Email: julia.balykina@gmail.com

References

  1. Coyne K.S., Sexton C.C., Irwin D.E., Kopp Z.S., Kelleher C.J., Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJUInt 2008;101:1388-1395.
  2. Reeves P., Irwin D., Kelleher C., Milsom I., Kopp Z., Calvert N., Lloyd A. The Current and Future Burden and Cost of Overactive Bladder in Five European Countries. Eur Urol. 2006;50:1050-1057.
  3. Lucas M.G., Bosch R.J., Burkhard F.C., Cruz F., Madden T.B., Nambiar A.K., Neisius A., de Ridder D.J., Tubaro A., Turner W.H., Pickard R.S.; European Association of Urology. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur Urol. 2012;62(6):1130-1142.
  4. Brown J.S., Vittinghoff E., Wyman J.F., Stone K.L., Nevitt M.C., Ensrud K.E., Grady D. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J. Am Geriatr Soc. 2000;48(7):721-725.
  5. Wein A.J., Rackley R.R. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J. Urol. 2006;175(3 Pt 2):S5-10.
  6. Semins M.J., Chancellor M.B. Diagnosis and management of patients with overactive bladder syndrome and abnormal detrusor activity. Nat Clin Pract Urol. 2004;1(2):78-84.
  7. Blok B. et al. Persistence with antimuscarinics in a European study of patients with overactive bladder syndrome. IUGA 34th Annual Meeting, Italy, June 16-20, 2009.
  8. Инструкция по применению лекарственного препарата для медицинского применения Ботокс®
  9. Инструкция по применению лекарственного препарата для медицинского применения Лантокс®
  10. Инструкция по применению лекарственного препарата для медицинского применения Бетмига®
  11. Cui Y., Zong H., Yang C., Yan H., Zhang Y. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol. 2014;46(1):275-284.
  12. Maman K., Aballea S., Nazir J., Desroziers K., Neine M.E., Siddiqui E., Odeyemi I., Hakimi Z. Comparative Efficacy and Safety of Medical Treatments for the Management of Overactive Bladder: A Systematic Literature Review and Mixed Treatment Comparison. Eur Urol. 2014;65(4):755-765.
  13. Chapple C.R., Cardozo L., Nitti V.W., Siddiqui E., Michel M.C. Mirabegron in Overactive Bladder: A Review of Efficacy, Safety, and Tolerability. Neurourology and Urodynamics. Neurourol Urodyn. 2014;33(1):17-30.
  14. Tyagi P., Tyagi V., Chancellor M. Mirabegron: a safety review. Expert Opin Drug Saf. 2011;10(2):287-294.
  15. Sacco E., Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol 2012:1-10.
  16. Bridgeman M.B., Friia N.J., Taft C., Shah M. Mirabegron: p3-Adrenergic Receptor Agonist for the Treatment of Overactive Bladder. Ann Pharmacother 2013;47: (7-8):1029-1038.
  17. Gras J. Mirabegron for the treatment of overactive bladder. Drugs of Today 2012; 48(1): 25-32.
  18. Bhide A.A., Digesu G.A., Fernando R., Khullar V. Use of mirabegron in treating overactive bladder. Int Urogynecol J. 2012;23(10):1345-1348.
  19. Caremel R., Loutochin O., Corcos J. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder? Int Urogynecol J. 2014;25(2):165-167.
  20. Igawa Y., Aizawa N., Homma Y. Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder. Korean J. Urol 2010;51:811-818.
  21. Aballea S., Maman K., Thokagevistk K., Nazir J., Odeyemi I.A., Hakimi Z., Garnham A., Toumi M. Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom. Clin Drug Investig. 2015;35(2):83-93.
  22. Mayr C.A., Shepherd J.P. Cost-effectiveness of novel therapies for overactive bladder. Expert Rev. Pharmacoecon. Outcomes Res. 2014:1-9.
  23. Xie J., et al. Cost-Effectiveness Analysis of Mirabegron vs. Tolterodine Extended Release in the Treatment of Overactive Bladder in the United States. Value in Health 2012: A 277-575.
  24. Sanford M., et al. Economics of Overactive Bladder. Curr Bladder Dysfunct Rep 2014; 9:52-57.
  25. Об утверждении отраслевого стандарта «клинико-экономические исследования. Общие положения»: приказ № 163 Министерства здравоохранения Российской Федерации от 27.05.2011
  26. Авксентьева М.А., Герасимов Б.В., Сура М.В. Клинико-экономический анализ (оценка, выбор медицинских технологий и управления качеством медицинской помощи) / Под ред. Воробьева П.А. М.: Ньюдиамед, 2004. 404 с.
  27. Белоусов Ю.Б. Планирование и проведение клинических исследований лекарственных средств. М.: Общество клинических исследователей, 2000. 579 с.
  28. Walley T., Haycox A., Boland A. Pharmacoeconomics. Elsevier Health Sciences, 2004. 216 р.
  29. Adapted from Brosa M., Gisbert R., Rodriguez Barrios J.M., Soto J. Principios, metodos y aplicaciones del analisisdel impacto presupuestario en sanidad. Pharma coeconomics Spanish Research Articles 2005;2:65-79.
  30. Sendi P.P., Briggs A.H. Affordability and cost-effectiveness: decision making on the cost-effectiveness plane. HealthEcon 2001;10:675-680.
  31. URL: www.medlux.ru
  32. Сайт Государственного реестра лекарственных средств. http://grls.rosminzdrav.ru
  33. Постановление Правительства РФ № 1273 «О программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2015 год и на плановый период 2016 и 2017 годов» от 28.11.2014
  34. Информационный портал ОМС Санкт-Петербурга
  35. Khullar V., Amarenco G., Angulo J.C., Cambronero J., H0ye K., Milsom I., Radziszewski P., Rechberger T., Boerrigter P., Drogendijk T., Wooning M., Chapple C. Efficacy and Tolerability of Mirabegron, a b3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European - Australian Phase 3 Trial. Eur Urol. 2013:63(2)283-295.
  36. Chapple C.R., Rechberger T., Al-Shukri S., Meffan P., Everaert K., Huang M., Ridder A; YM-905 Study Group. Randomized, doubleblind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303-310.
  37. Chapple C., Sievert K.D., MacDiarmid S., Khullar V., Radziszewski P., Nardo C., Thompson C., Zhou J., Haag-Molkenteller C. Onabotulinumtoxin A 100 U. significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, doubleblind, placebo-controlled trial. Eur Urol. 2013;64(2):249-256.
  38. Приказ МЗ РФ № 700н от 09.11.2012 г. «Об утверждении стандарта первичной медико-санитарной помощи при нервномышечной дисфункции мочевого пузыря»
  39. Wagg A. et al. Persistence with mirabegron, a beta-3 adrenoceptoragonist, versus antimuscarinics in patients with overactivebladder: Early UK experience. EAU2015 - 30th Annual Congress of the European Association of Urology (EAU) and the 16th International Meeting of the European Association of Urology Nurses (EAUN), March 20-24, 2015, Madrid, Spain.
  40. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-15.
  41. Wagner T.H., Hu T.W., Bentkover J., LeBlanc K., Stewart W., Corey R., Zhou Z., Hunt T. Health-related consequences of overactive bladder. Am J. Manag Care. 2002;8(19 Suppl.):S598-607.
  42. Bolge S.C., Cerulli A., Kahler K.H., et al. Impact of successful treatment of overactive bladder on health care resource use and productivity. Drug Benefit Trends 2006;18:244-255.
  43. Castro Diaz D., Rebollo P., Gonzάlez-Segura Alsina D. Comorbidity associated to overactive bladder syndrome. [ArticleinSpanish] Arch Esp Urol. 2009;62(8):639-645.
  44. Kobelt G., Johnson L., Mattiasson A. Cost effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodynam 1998, 17:599-611.
  45. Авксентьева М.В., Герасимова К.В., Хачатрян Г.Р., Фролов М.Ю., Омельяновский В.В., Авксентьев Н.А. Фармакоэкономическое исследование применения препарата солифенацин для лечение ургентного недержания мочи у пациентов с синдромом гиперактивного мочевого пузыря. Урология. 2014;5:56-61
  46. Haab F., Cardozo L., Chapple C., Ridder A.M.; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47:376-384.
  47. Speakman M., Khullar V., Mundy A., Odeyemi I., Bolodeoku J. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin 2008;24(8):2173-2179.
  48. Siddiqui N.Y., Amundsen C.L., Visco A.G., Myers E.R., Wu J.M. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J. Urol 2009;182:2799-804.
  49. Приказ Минздрава РФ №1219н от 20.12.2012 г. «Об утверждении стандарта первичной медико-санитарной помощи при депрессиях легкой и средней степени тяжести и смешанном тревожном и депрессивном расстройстве в амбулаторных условиях психоневрологического диспансера (диспансерного отделения, кабинета)»
  50. Федеральный закон от 29.12.2006 N. 255-ФЗ (ред. от 03.12.2011) «Об обязательном социальном страховании на случай временной нетрудоспособности и в связи с материнством»
  51. Территориальный орган Федеральной службы государственной статистики по г. Санкт-Петербургу и Ленинградской области, официальный сайт, http://petrostat. gks.ru
  52. Chu F., Smith N., Uchida T. Efficacy and Safety of Solifenacin Succinate 10 mg Once Daily: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trialin Patients With Overactive Bladder. Curr Ther Res Clin Exp. 2009;70(6):405- 420.
  53. Temml C., Heidler S., Ponholzer A., Madersbacher S. Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur. Urol. 2005;48:622-627.
  54. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-78.
  55. Johansson C., Molander U., Milsom I., Ekelund P. Association between urinary incontinence and urinary tract infections, and fractures in postmenopausal women. Maturitas. 1996;23(3):265-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies